Founding Partner
Biotechnology patent protection in the USA is not just about whether an invention is patentable. For research institutions, universities, and companies working on federally funded projects, ownership, disclosure timing, and collaboration agreements can determine who actually controls the resulting patent.
Most conversations about biotechnology patent protection in the USA focus on the science: is the invention novel, is it non-obvious, and does it clear Section 101? Those questions matter. But for research institutions, universities, and companies working with academic collaborators, there is a layer underneath the science that determines who actually owns the resulting patent before any of those questions are even asked.
Gearhart Law works with research institutions, biotech companies, and academic spinouts to navigate that layer. This post covers the ownership, funding, and collaboration issues that come up before a patent application is ever filed.
Who Owns the Invention: Research Institutions and the Bayh-Dole Act
If your biotechnology research was funded in whole or in part by a federal grant or contract, the Bayh-Dole Act governs who owns the resulting patent rights. Understanding this law is essential for any university, research hospital, or biotech company working with federal funding.
What the Bayh-Dole Act Allows
The Bayh-Dole Act of 1980 allows universities, nonprofit research institutions, and small businesses to retain ownership of inventions developed under federally funded research, rather than the government automatically owning them. This was a significant shift from prior policy and is widely credited with accelerating the commercialization of federally funded research, including a large share of modern biotechnology.
To retain ownership, the institution must meet specific deadlines under the standard patent rights clause. The invention must be disclosed to the federal funding agency within two months of the inventor disclosing it in writing to the institution’s patent personnel. The institution must then make a written election to retain title within two years of that disclosure, or no more than 60 days before the end of any one-year statutory bar period if that comes sooner. Once title is elected, an initial patent application must be filed within one year of the election date, with extensions available at the agency’s discretion.
What Happens If You Miss a Deadline
Missing these deadlines is not a minor administrative issue. Since a 2018 regulatory update, the 60-day window that previously allowed institutions to retroactively correct a missed disclosure or election deadline was eliminated. Under the current rule, the government can object and obtain title at any time after discovering a missed deadline, with no time limit on when that request can be made.
This means an institution could lose ownership of a valuable biotechnology patent years later due to a disclosure or election step that was missed early in the process.
March-In Rights
The Bayh-Dole Act also gives the federal government limited march-in rights, allowing it to require the patent holder to license the invention to others under certain narrow circumstances, primarily when the patent holder has failed to commercialize the invention.
March-in rights have rarely been exercised since the law was passed, but the scope of when they can be used has become a subject of ongoing policy debate, particularly around drug pricing. Research institutions and licensees should stay aware of this evolving area.
Joint Research and Ownership in Collaborative Biotech Projects
Biotechnology research increasingly happens across institutional lines. A university lab partners with a pharmaceutical company. Two research institutions co-develop a platform technology. A biotech startup licenses foundational research from an academic lab.
Each of these arrangements creates a question that needs to be answered before any patent is filed: who owns what?
Why Joint Ownership Gets Complicated
When two or more parties contribute to an invention, the resulting patent may have joint inventors and joint owners. Under U.S. patent law, joint owners generally each have an independent right to use, license, or exploit the patent without needing permission from the other owners, unless the parties have agreed otherwise in writing.
For a biotechnology company that has invested heavily in developing a technology, discovering that a research collaborator can license the same patent to a competitor without consent is a serious problem.
Why a Collaboration Agreement Matters
A clear collaboration or sponsored research agreement, signed before the research begins, should address:
- Who will own any resulting inventions, and how will joint ownership be allocated if more than one party contributes
- Whether one party will have exclusive rights to license or commercialize the technology
- How patent prosecution decisions will be made and who will control the process
- What happens to ownership and licensing rights if the collaboration ends
These agreements are not a formality. They determine the commercial value of the research before a single experiment has been run.
Gearhart Law helps research institutions, biotech companies, and academic spinouts navigate ownership, funding compliance, and collaboration agreements before a single patent application is filed. Reach out for a free half-hour consultation.
Publishing vs. Patenting: A Tension Specific to Academic Research
Academic researchers operate under pressure to publish that does not exist in the same way for purely commercial research teams. This creates a real tension with patent strategy that research institutions need to manage actively.
The One-Year Clock
In the United States, public disclosure of an invention, including publication in a journal, a conference presentation, or even a dissertation defense, starts a one-year grace period during which a patent application can still be filed.
After that year, U.S. patent rights are lost. In most other countries, there is no grace period at all. A publication before filing can eliminate international patent rights immediately.
Coordinating Tech Transfer and Research Timelines
The practical answer is not to stop publishing. It is to coordinate with your institution’s technology transfer office or patent counsel before any public disclosure, not after. Most universities have an invention disclosure process specifically designed to flag potentially patentable research before it is submitted for publication.
Researchers who bypass this process, often without realizing the legal stakes, are the most common source of lost patent rights in academic biotechnology.
Build Biotechnology Patent Protection on a Solid Foundation
The science is only part of what determines whether a biotechnology invention is properly protected. Ownership under federal funding rules, collaboration agreements between research partners, and the timing of publication relative to filing all shape whether a patent ends up belonging to the institution that did the work and whether it holds up once granted.
Gearhart Law works with research institutions, biotechnology companies, and academic spinouts throughout New Jersey and beyond to navigate this layer before problems arise. Leave your details, and we will be in touch, or call 908.273.0700 for a free half-hour consultation.
Frequently Asked Questions About Biotechnology Patent Protection in the USA
1. What is the Bayh-Dole Act, and how does it affect biotechnology patents?
The Bayh-Dole Act allows universities, nonprofit research institutions, and small businesses to retain ownership of patents developed using federal funding, rather than the government owning them automatically. It requires the institution to meet specific disclosure and election deadlines to keep that ownership. Missing those deadlines can result in the government requesting title to the invention.
2. Who owns a patent developed through a university and company collaboration?
It depends entirely on the collaboration agreement signed before the research began. Without a clear agreement, joint inventors generally become joint owners, and under U.S. law, each owner can independently license the patent to others without the consent of the other owners. This is why a sponsored research or collaboration agreement addressing ownership, licensing rights, and prosecution control should be in place before joint research begins.
3. Can I publish my research and still get a patent?
Yes, but timing matters. In the United States, you have one year from the date of public disclosure to file a patent application. After that, domestic rights are lost. Most other countries have no grace period at all, so a publication before filing can eliminate international rights immediately. Coordinate with a patent attorney or your institution’s technology transfer office before submitting research for publication.
4. What are march-in rights under the Bayh-Dole Act?
March-in rights allow the federal government to require a patent holder to license a federally funded invention to others under narrow circumstances, typically when the patent holder has failed to commercialize it. These rights have rarely been exercised since 1980, though their scope has become a subject of ongoing policy debate. Research institutions working with federal funding should stay informed about developments in this area.
5. What happens if my research institution misses a Bayh-Dole deadline?
Missing a disclosure or election deadline under the Bayh-Dole Act can result in the federal funding agency requesting title to the invention. Under current rules, there is no time limit on when the government can make this request after discovering noncompliance. Institutions that discover a missed deadline should notify the funding agency and seek to correct it as soon as possible, since acting in good faith can influence whether the agency grants relief.
6. How is biotechnology patent ownership different for federally funded research versus privately funded research?
Privately funded biotechnology research is generally owned according to the terms of employment or contractor agreements, without the disclosure and election requirements that apply to federal funding. Federally funded research is subject to the Bayh-Dole Act, which requires specific compliance steps to retain ownership. Companies and institutions working with both types of funding need to track which rules apply to which projects.
7. Should a research institution have a standard collaboration agreement for biotech partnerships?
Yes. A standard template that addresses ownership, licensing rights, prosecution control, and what happens if the collaboration ends helps avoid disputes before they happen and speeds up the process of entering new partnerships. Gearhart Law works with research institutions to develop and review collaboration agreements that protect their interests in joint biotechnology research.